Notably, we found that mTOR inhibition was sufficient to decrease fusion-TFE3 transcript levels in both inducible, as well patient-derived tRCC cell lines, consistent with mTOR’s previously described role in transcription100,101. The gene discussed is TFE3; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.